Diabetes

Tirzepatide noninferior, superior to semaglutide for T2DM

(HealthDay)—The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide, is noninferior and superior to semaglutide for reducing glycated hemoglobin levels among patients ...